Anavex Life Sciences Corp. (AVXL) Receives Daily News Impact Rating of 0.24

Press coverage about Anavex Life Sciences Corp. (NASDAQ:AVXL) has been trending somewhat positive on Tuesday, AlphaOne reports. AlphaOne, a unit of Accern, identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anavex Life Sciences Corp. earned a news impact score of 0.24 on AlphaOne’s scale. AlphaOne also gave news stories about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the company’s share price in the near term.

These are some of the news headlines that may have effected Alpha One Sentiment’s scoring:

Insider Buying and Selling by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)

A number of equities research analysts recently commented on the company. Zacks Investment Research upgraded Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research report on Thursday, June 8th. Noble Financial reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Sunday, May 14th. Finally, Maxim Group set a $15.00 price objective on Anavex Life Sciences Corp. and gave the stock a “buy” rating in a research note on Monday, May 22nd.

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) traded down 0.7412% during trading on Tuesday, reaching $5.3699. The company had a trading volume of 179,310 shares. The firm’s market capitalization is $222.19 million. Anavex Life Sciences Corp. has a 1-year low of $2.43 and a 1-year high of $8.30. The firm has a 50-day moving average of $5.83 and a 200 day moving average of $5.27.

TRADEMARK VIOLATION NOTICE: “Anavex Life Sciences Corp. (AVXL) Receives Daily News Impact Rating of 0.24” was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with's FREE daily email newsletter.

Leave a Reply